Company intelligence / Profile preview
rEVO Biologics
Framingham, Massachusetts, United Statesrevobiologics.com ↗
- Ownership
- Private
- Employees
- ~137
- Development stage
- Other
01
Overview
The company's lead product ATryn (Antithrombin Recombinant) is approved for use in patients with hereditary antithrombin deficiency. They were exploring additional applications for ATryn including early onset preeclampsia through a Phase 3 clinical trial called PRESERVE-1.
- Therapeutic areas
- Women's HealthHematologyCardiovascularOphthalmology
- Modalities
- Recombinant proteinsTherapeutic proteinsMonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Mayo Clinic
Beyond the preview
Go deeper on rEVO Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rEVO Biologics.